July 7, 2023

Cipla issues voluntary Nationwide recall of 6 batches of albuterol sulfate inhalation aerosol, 90 mcg (200 metered inhalation) due to container defect

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **PrimeTherapeutics.com/DrugRecalls** to review the latest FDA drug recalls.

About this recall:

Cipla Limited announced that its wholly-owned subsidiary, Cipla US, is voluntarily recalling six batches of albuterol sulfate inhalation aerosol, 90 mcg (200 metered inhalation), manufactured in November 2021 to the consumer level. The company is initiating a recall in the United States due to a market complaint for one single inhaler (Batch number IB20056), where leakage was observed through the inhaler valve. Out of an abundance of precaution, the above mentioned six batches manufactured using the same lot of valves are being recalled. The product is packaged in 17 mL plain aluminum aerosol canisters integrated with a dose counter, coupled with a plastic actuator and dust cap. Each pack claims 200 metered inhalations. Associated codes are NDC-69097-142-60. These six batches were distributed nationwide to wholesalers and retailers.

The product is used for the treatment and prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise induced bronchospasm.

What this means to you:

There is a reasonable probability that failure to deliver the recommended dose to treat the respiratory symptoms of an acute asthma exacerbation such as wheezing, coughing, shortness of breath, and bronchospasms, due to device defect, may be life-threatening. There were no adverse events reported for albuterol sulfate inhalation aerosol 90 mcg related to this recall.

Consumers with questions adverse reactions or quality problems regarding these six batches can contact Cipla Customer Service at **844.CIPLAUS** (**844.247.5287**) Monday–Friday, 8:30 a.m.–5 p.m. Eastern Standard Time (EST), or email **Cipla.CS@Cipla.com**. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.

All brand names are property of their respective owners.
FOR_176350 07/25 © 2025 Prime Therapeutics Management LLC, A Prime Therapeutics LLC Company